Avalon’s Laboratory Services MSO to Launch Sales of Proprietary FDA-Registered External Male Catheter Device

Rhea-AI Summary

Avalon GloboCare Corp. (NASDAQ: ALBT) announced that Laboratory Services MSO, (LSM), in which Avalon owns a 40% stake, will begin manufacturing and selling the GeeWhiz External Condom Catheter, an FDA-registered male incontinence device. The product launch is planned for Q3 2024. The device is approved for Medicare reimbursement and supported by several private insurers.

The global male urinary incontinence market, valued at $6.37 billion in 2022, is projected to grow at a CAGR of 5.87% from 2023 to 2030. This growth is driven by increasing incontinence prevalence, an aging population, and technological advancements. The GeeWhiz catheter aims to provide enhanced comfort, security, and ease of use for men with urinary incontinence and bladder control issues.

Positive

• FDA-registered device approved for Medicare reimbursement
• Supported by several private insurance providers
• Entering a market valued at $6.37 billion in 2022
• Market expected to grow at 5.87% CAGR from 2023 to 2030
• Product launch planned for Q3 2024

Negative

• None.

Medical Device Analyst

The launch of the GeeWhiz External Condom Catheter by Avalon's Laboratory Services MSO is a strategic move into a growing market. With the global male urinary incontinence market valued at $6.37 billion in 2022 and projected to grow at a 5.87% CAGR, this product enters a lucrative space. The device's FDA registration and Medicare reimbursement approval are significant advantages, potentially accelerating market adoption.

However, it's important to note that Avalon only owns a 40% stake in LSM, limiting its direct benefit from sales. The success of this product will depend on its ability to differentiate from existing solutions and capture market share in a competitive landscape. While the market potential is promising, investors should carefully consider Avalon's partial ownership and the product's ability to stand out in a crowded field.

Healthcare Market Analyst

The GeeWhiz catheter enters a market driven by demographic trends and increasing awareness of male incontinence issues. The aging population is a key factor supporting market growth, as incontinence prevalence increases with age. The device's approval for Medicare reimbursement is particularly significant, given the target demographic.

However, market penetration may face challenges. The male incontinence market is sensitive, with users often reluctant to adopt new solutions. The success of GeeWhiz will largely depend on its comfort and discretion advantages over existing products. Additionally, while several private insurers support the device, widespread coverage will be important for broad adoption. Avalon and LSM must execute a thoughtful marketing strategy to overcome potential stigma and highlight the product's benefits to both patients and healthcare providers.

Financial Analyst

Avalon's 40% stake in LSM presents a mixed financial picture. While it provides exposure to the growing male incontinence market, it also limits the direct financial impact on Avalon's bottom line. Investors should note that the company's revenue from this product will be proportional to its ownership stake.

The market's projected 5.87% CAGR suggests steady growth potential, but it's essential to consider the competitive landscape and Avalon's ability to capture market share. The Medicare reimbursement approval is a positive factor that could drive adoption and sales. However, the financial impact on Avalon will depend on LSM's execution, marketing effectiveness and the product's performance against established competitors. Investors should monitor initial sales figures and market reception closely to gauge the potential long-term value of this venture for Avalon.

Device is Approved for Reimbursement by Medicare and is Supported by Several Private Insurance Providers

FREEHOLD, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that Laboratory Services MSO, LLC (“LSM”) has begun manufacturing the GeeWhiz External Condom Catheter, a patented, FDA-registered, in-market, male incontinence device. LSM plans to launch its sales of the GeeWhiz External Condom Catheter in the third quarter of 2024. Avalon owns a 40% interest in LSM.

According to Grand View Research, the global male urinary incontinence market size was valued at $6.37 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 5.87% from 2023 to 2030. The market is expected to grow steadily due to the increasing prevalence of incontinence, an aging population, and advancements in product technology. This growth reflects a broader awareness and demand for effective management solutions for urinary incontinence among men.

“We are thrilled to introduce the GeeWhiz External Condom Catheter to the market in the anticipated upcoming launch,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. "The GeeWhiz External Condom Catheter represents a significant advancement in managing male incontinence. Not only is this device FDA-registered and approved for reimbursement by Medicare, but it is also supported by several private insurance providers.”

“The GeeWhiz External Condom Catheter is meticulously engineered to address the needs of men with urinary incontinence and bladder control issues. Its innovative design aims to provide enhanced comfort, security, and ease of use, ultimately improving the quality of life for users. We are confident that this product will meet a critical need in the market and deliver substantial benefits to patients and healthcare providers alike. The anticipated upcoming launch of GeeWhiz underscores our commitment to advancing healthcare solutions and expanding our impact in the medical device industry,” concluded Dr. Jin.

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (NASDAQ: ALBT) is a commercial stage company dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services. Avalon is working to establish a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results. The Company also provides laboratory services, offering a broad portfolio of diagnostic tests, including drug testing, toxicology, and a broad array of test services, from general bloodwork to anatomic pathology, and urine toxicology. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.

For the latest updates on Avalon GloboCare’s developments, please follow our twitter at @avalongc_avco

Forward-Looking Statements

Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates, however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company’s commercialization, distribution and sales of its products and the ability to compete with other similar products. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Form 8-Ks filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com

FAQ

What is the GeeWhiz External Condom Catheter being launched by Avalon GloboCare (ALBT)?

The GeeWhiz External Condom Catheter is an FDA-registered male incontinence device designed to provide enhanced comfort, security, and ease of use for men with urinary incontinence and bladder control issues.

When is Avalon GloboCare (ALBT) planning to launch sales of the GeeWhiz External Condom Catheter?

Avalon GloboCare plans to launch sales of the GeeWhiz External Condom Catheter in the third quarter of 2024.

Is the GeeWhiz External Condom Catheter approved for reimbursement by Medicare?

Yes, the GeeWhiz External Condom Catheter is approved for reimbursement by Medicare and is also supported by several private insurance providers.

What is the projected growth of the global male urinary incontinence market that Avalon GloboCare (ALBT) is entering with the GeeWhiz catheter?

The global male urinary incontinence market is anticipated to grow at a compound annual growth rate (CAGR) of 5.87% from 2023 to 2030, according to Grand View Research.